![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » President’s Panel Calls for Value-Based Pricing, Increased Competition to Lower Cancer Drug Prices
President’s Panel Calls for Value-Based Pricing, Increased Competition to Lower Cancer Drug Prices
March 14, 2018
The President’s Cancer Panel highlighted the sharp increase in U.S. cancer drug prices in a 70-page report to President Trump, calling for more value-based pricing, more competition in the drug market and “meaningful communication” about treatment options.
The panel recommended the use of a widely accepted value framework as a key step toward value-based pricing, saying an ideal framework would “integrate information on clinical outcomes, toxicities, impact on quality of life, and costs.”
Such a framework would “inform negotiations between drug manufacturers and payers and… could guide development of value-based payment models,” said the three-member panel, including Barbara Rimer, dean of the Gillings School of Global Public Health at the University of North Carolina , Owen Witte, a professor at UCLA, and actor and cancer survivor Hill Harper.
Upcoming Events
-
21Oct